Skip to main content

Advertisement

Table 1 Frequency of treatment-emergent adverse events (TEAEs) from baseline to treatment endpoint by treatment group

From: A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Event ATX + MPH N= 9 n(%) ATX + PBO N= 12 n(%)
Initial insomnia 1 (11.1) 2 (16.7)
Rash 1 (11.1) 0 (0.0)
GI discomfort 1 (11.1) 0 (0.0)
Cardiac SE 1 (11.1) 0 (0.0)
Toothache 1 (11.1) 0 (0.0)
Vomiting 1 (11.1) 2 (16.7)
Abdominal pain 0 (0.0) 1 (8.3)
BP Increase 0 (0.0) 1 (8.3)
Hand fracture 0 (0.0) 1 (8.3)
Headache 0 (0.0) 2 (16.7)
Insomnia 0 (0.0) 1 (8.3)
Irritability 0 (0.0) 1 (8.3)
Nausea 0 (0.0) 2 (16.7)
Rhinitis 0 (0.0) 2 (16.7)
  1. Key: GI, gastrointestinal; SE, supraventricular extrasystoles; BP, blood pressure
  2. No significant differences were found between groups.